An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual InnovationNew York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (
NASDAQASBP) ("Aspire" or the "Company")...
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance SupplementNew product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout market
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual AspirinInitial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase AgreementNEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology (Nasdaq:ASBP)(Nasdaq:ASBPW), today announced that it entered into a definitive Securities Purchase Agreement (the "Agreement") on February 19, 2025, pursuant to which the Company issued to the Buyers a senior secured convertible debenture (the "Debenture"). The Debenture is only convertible in the event of a default or at the Company's discretion. The closing of the transaction is expected to occur on February 20, 2025 (the "Closing Date"). The transaction will result in gross proceeds to the Company of $3.0 million. Proceeds from the transaction will support the Company's general working capital and operating expenses.
